| Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.J Allergy Clin Immunol Pract | PMID 34848381无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.Br J Clin Pharmacol | PMID 35029306PMC9302693 | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.Allergy | PMID 35034364PMC9305228 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.Br J Clin Pharmacol | PMID 35072287PMC9305466 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.J Diabetes Investig | PMID 35199478PMC9248426 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.Eur J Neurol | PMID 35258154无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial.J Eur Acad Dermatol Venereol | PMID 35297108无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.Eur J Neurol | PMID 35302681无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes.Diabetes Obes Metab | PMID 35322535无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.J Gastroenterol Hepatol | PMID 35342997无 PMCID | 2022-Jul | 0.95 | Study is not oncology-related; it investigates duodenal ulcer healing and H. pylori eradication, not a malignant neoplasm. No time-to-event efficacy endpoint is present. | 待处理 |
| A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.Gastric Cancer | PMID 35352176无 PMCID | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.Lancet Respir Med | PMID 35364018无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Gastroenterol Hepatol | PMID 35366419无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.Ann Oncol | PMID 35395383无 PMCID | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.J Allergy Clin Immunol Pract | PMID 35398549无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.J Rheumatol | PMID 35428720无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SCOPE 2 - Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography.Clin Oncol (R Coll Radiol) | PMID 35466013无 PMCID | 2022-Jul | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial.Am J Hematol | PMID 35472008PMC9325377 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.Haemophilia | PMID 35475308PMC9542908 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.Br J Haematol | PMID 35476316PMC9541243 | 2022-Jul | 0.85 | The record describes a secondary analysis of a Phase 3, randomized trial (JAKARTA) and a Phase 2 trial (JAKARTA2) evaluating fedratinib in myelofibrosis. While it meets criteria for oncology, human, randomized, phase 3, and drug intervention, it does not meet the time-to-event efficacy endpoint criterion. The abstract reports only categorical response rates (spleen and symptom response) at a fixed timepoint, with no mention of time-to-event outcomes like OS, PFS, or Kaplan-Meier analyses. Additionally, the report itself is a subgroup analysis (low-platelet patients), not the primary trial report. Therefore, it is ineligible. | 待处理 |
| Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.Lancet Neurol | PMID 35483387无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).Eur J Cancer | PMID 35489301无 PMCID | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres.Radiother Oncol | PMID 35513132无 PMCID | 2022-Jul | 0.45 | While the record is from a Phase III randomized oncology trial, the abstract does not report any survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for eligibility. It is a technical planning quality assurance study. | 待处理 |
| Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.Korean J Intern Med | PMID 35526858PMC9271723 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.Eur J Cancer | PMID 35569283无 PMCID | 2022-Jul | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.Lancet Haematol | PMID 35597252无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.Clin Lung Cancer | PMID 35613998PMC9634857 | 2022-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.Ann Hematol | PMID 35643952无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.Lung Cancer | PMID 35660972无 PMCID | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.Lancet Oncol | PMID 35688173PMC10305087 | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol | PMID 35690073PMC9630160 | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.Paediatr Drugs | PMID 35698000PMC9205811 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.Lancet Neurol | PMID 35716692无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.Am J Clin Dermatol | PMID 35857179PMC9334431 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.NEJM Evid | PMID 38319255无 PMCID | 2022-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.Arthritis Res Ther | PMID 35773713PMC9245232 | 2022-Jun-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.Nephrol Dial Transplant | PMID 34240198PMC9217650 | 2022-Jun-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.Antimicrob Agents Chemother | PMID 35502922PMC9211436 | 2022-Jun-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.J Clin Oncol | PMID 35230884PMC9197353 | 2022-Jun-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.J Clin Oncol | PMID 35316080无 PMCID | 2022-Jun-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.Lancet | PMID 35717989无 PMCID | 2022-Jun-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.J Clin Endocrinol Metab | PMID 35325149PMC9202723 | 2022-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.J Clin Endocrinol Metab | PMID 35405011PMC9202717 | 2022-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.N Engl J Med | PMID 35704479PMC9717677 | 2022-Jun-16 | 0.95 | The record is a Phase III randomized trial with a time-to-event endpoint for a human oncology condition (anal cancer). However, it is ineligible because the intervention is not a drug-containing regimen for treating an established malignant neoplasm; it is a prevention trial using procedural and topical interventions for precancerous lesions. | 待处理 |
| Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.Blood Adv | PMID 35143644PMC9198908 | 2022-Jun-14 | 0.55 | The trial is a Phase III randomized controlled trial in oncology (hematological malignancy) with time-to-event endpoints (GRFS, OS, PFS) and reports original results. However, the core intervention is a post-transplant immunosuppressive regimen (cyclophosphamide, cyclosporine, mycophenolic acid) for GVHD prevention, not a primary antineoplastic drug therapy for the malignancy itself. The review criteria require a 'drug-containing intervention' for the malignancy. This study is ambiguous on whether the immunosuppressive drugs are considered the 'drug intervention' in the oncologic sense required for eligibility. Therefore, cannot definitively set is_eligible to true without clarifying this specific criterion. | 待处理 |
| Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.Sleep | PMID 34358324PMC9189976 | 2022-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.Clin Cancer Res | PMID 35275197PMC9297529 | 2022-Jun-13 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities.J Neurodev Disord | PMID 35690720PMC9188139 | 2022-Jun-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.Lancet | PMID 35691323无 PMCID | 2022-Jun-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).Clin Infect Dis | PMID 34467969PMC9187327 | 2022-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |